Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding 90Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients

Saved in:
Bibliographic Details
Published in:Blood 2014-05, Vol.123 (19), p.2953-2959
Main Authors: Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, Geisler, Christian H.
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carmustine - administration & dosage
Clinical Trials and Observations
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Cytarabine - administration & dosage
Disease-Free Survival
Etoposide - administration & dosage
Female
Humans
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell - therapy
Male
Melphalan - administration & dosage
Middle Aged
Multivariate Analysis
Neoplasm, Residual - diagnosis
Prognosis
Radioimmunotherapy
Stem Cell Transplantation - methods
Time Factors
Transplantation, Autologous
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding 90Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2013-12-541953